Pfizer Inc. (PFE)
Healthy Returns: Pfizer pulls sickle cell disease drug from markets – here's why it matters
Pfizer withdrew its sickle cell disease treatment Oxbryta. Meanwhile, Senators introduce new bill to fortify health-care cybersecurity following major attacks.
Lock In A Phenomenal Yield With Pfizer
Pfizer's stock has declined by 50% over several years, yet it maintains a nearly 6% dividend yield, making it a valuable long-term investment. The company's quarterly performance includes $13.3 billion in revenue, $2.7 billion in R&D expenditures, and a $0.6 adjusted EPS, with respectable growth. Pfizer's oncology investments, including the $40 billion Seagen acquisition, show substantial YoY revenue growth and a robust pipeline of new drugs.
3 Consistent Dividend Stocks for Passive Income: KO, PFE, MO
Everybody loves dividends, essentially investors' form of payday. And these companies have been paying shareholders consistently for years.
Pfizer offloads $3.3 bln stake in Sensodyne-maker Haleon
Pfizer offloaded shares worth roughly $3.26 billion in Haleon at 380 pence apiece, cutting its stake to 15% in the world's largest standalone consumer healthcare firm, a bookrunner said on Tuesday.
Pfizer: Growth From Oncology Franchise; Initiate With 'Buy'
Pfizer's acquisition of Seagen for $43 billion enhances its ADC technology, potentially expanding its oncology franchise and driving future growth. PFE's development of the oral GLP-1 receptor agonist, Danuglipron, aims to capture the growing obesity and diabetes treatment market by 2028. The Company anticipates 11.4% revenue growth, driven by oncology investments, M&A activities, and manufacturing optimization, despite challenges from declining COVID-related revenue.
Pfizer to offload about 5.9% stake in UK's Haleon, says bookrunner
Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon , a bookrunner said on Monday.
PFE vs. NVO: Which Stock Is the Better Value Option?
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks presents investors with the better value opportunity right now?
Pfizer: A 6% Yielding Value Deal
Pfizer remains an attractive capital return play with a 10X P/E ratio, despite concerns about post-COVID revenue declines. The oncology business shows promising growth, particularly with products like Xtandi and Lobrena, supporting Pfizer's long-term potential. Pfizer's guidance for FY 2024 EPS has been raised, indicating strong earnings potential and undervaluation by the market.
Pfizer (PFE) Rises But Trails Market: What Investors Should Know
Pfizer (PFE) closed the most recent trading day at $28.97, moving +0.14% from the previous trading session.
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of Pfizer's sickle cell disease treatment Oxbryta.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
PFE's decision is based on clinical data, which suggests that the overall benefit of the drug no longer outweighs the risk in the approved patient population.
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
